FABP4 and neoplasm: We next tested two compounds with potential to affect adipocyte–tumor cell interactions: a selective inhibitor of fatty acid-binding protein 4 (FABP4) (BMS309403) (5), and Atglistatin, a selective inhibitor of Adipocyte Triglyceride LIpase (ATGL) (57).